Medicines and supplements
CBD and other cannabinoids can affect other treatments or be affected by them. The review should include doses and frequency.
Responsible clinical decision
Medical cannabis does not mean zero risk. THC, CBD and other preparations are not interchangeable. An individual assessment should review the product, dose, medical history, medications and high-risk activities.
CBD and other cannabinoids can affect other treatments or be affected by them. The review should include doses and frequency.
Health authorities advise avoiding CBD, THC and cannabis during pregnancy or breastfeeding because of significant risks and uncertainties.
A personal or family history of psychosis, episodes of disorganization or problematic consumption require special care.
Certain CBD products have been associated with liver abnormalities. The clinical context and monitoring depend on the product and dose.
THC can affect coordination, judgment and reaction time. Do not drive or operate machinery while under its effects.
A label alone does not guarantee concentration, purity or freedom from contaminants. A non-standardized product changes the risk assessment.
Prepare an assessment to review medicines, background and risk activities with a professional.
Difficulty breathing, loss of consciousness, severe pain, seizures, marked confusion, thoughts of self-harm or psychotic symptoms require urgent care. CAMED does not replace an emergency hotline or emergency services.
Published and revised editorially on July 13, 2026. It does not replace individual medical valuation.
Next step
If you wish to know what information should be prepared, start with the CAMED assessment path.